Merck & Co., Inc. (MRK) trades at a trailing P/E of 16.9, forward P/E of 23.5. Trailing earnings yield is 5.92%, forward earnings yield 4.26%. PEG 2.11. Graham Number is $59.07.
Criteria proven by this page:
Overall SharesGrow Score: 83/100 with 7/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 39.4 | 1.34 | 3.85 | 3.88 | 3.32% |
| 2017 | 60.4 | -1.12 | 4.21 | 3.61 | 3.57% |
| 2018 | 30.4 | 0.20 | 7.07 | 4.47 | 2.74% |
| 2019 | 22.6 | 0.38 | 8.59 | 5.69 | 2.56% |
| 2020 | 27.9 | -1.02 | 7.79 | 4.75 | 3.15% |
| 2021 | 14.9 | 0.17 | 5.08 | 3.98 | 3.41% |
| 2022 | 19.3 | 1.75 | 6.11 | 4.74 | 2.50% |
| 2023 | 778.7 | -7.98 | 7.56 | 4.73 | 2.62% |
| 2024 | 14.7 | 0.00 | 5.44 | 3.93 | 3.11% |
| 2025 | 14.5 | 1.88 | 5.02 | 4.06 | 3.10% |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $2.04 | $39.81B | $5.69B | 14.3% |
| 2017 | $0.93 | $40.12B | $2.57B | 6.4% |
| 2018 | $2.32 | $42.29B | $6.22B | 14.7% |
| 2019 | $3.82 | $46.84B | $9.84B | 21% |
| 2020 | $2.78 | $41.52B | $7.07B | 17% |
| 2021 | $5.14 | $48.7B | $13.05B | 26.8% |
| 2022 | $5.71 | $59.28B | $14.52B | 24.5% |
| 2023 | $0.14 | $60.12B | $365M | 0.6% |
| 2024 | $6.74 | $64.17B | $17.12B | 26.7% |
| 2025 | $7.28 | $65.01B | $18.25B | 28.1% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $5.12 | $2.82 – $8.42 | $66.75B | $66.39B – $67.37B | 14 |
| 2027 | $9.69 | $9.53 – $10.10 | $70.23B | $68.83B – $71.82B | 13 |
| 2028 | $10.75 | $8.93 – $13.25 | $74.93B | $74.92B – $74.94B | 8 |
| 2029 | $10.36 | $10.08 – $10.60 | $74.56B | $73B – $75.83B | 6 |
| 2030 | $10.16 | $9.89 – $10.39 | $74.14B | $72.58B – $75.4B | 6 |
